Published in EMBO J on May 20, 2004
Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol (2010) 8.55
Recent progress in the biology and physiology of sirtuins. Nature (2009) 7.73
Sirtuins in mammals: insights into their biological function. Biochem J (2007) 7.60
Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A (2006) 7.00
Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell (2005) 6.79
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A (2008) 6.24
SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell (2009) 6.09
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
Transcriptional control of the inflammatory response. Nat Rev Immunol (2009) 5.20
Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab (2009) 5.02
Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science (2009) 4.80
The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol (2009) 4.61
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell (2009) 3.91
MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol (2012) 3.78
Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature (2013) 3.76
Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol (2008) 3.74
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol (2005) 3.50
Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science (2013) 3.40
Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab (2011) 3.38
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol (2006) 3.37
SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab (2008) 3.35
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev (2007) 3.16
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci (2009) 2.80
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol (2008) 2.73
Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J Biol Chem (2006) 2.59
NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta (2010) 2.55
SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 2.49
SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab (2007) 2.42
Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol (1985) (2008) 2.40
AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab (2010) 2.40
The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies. Brain Res Rev (2008) 2.39
Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J (2005) 2.30
AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) (2011) 2.26
SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol (2005) 2.24
Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov (2012) 2.22
Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem (2010) 2.19
Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol (2012) 2.12
The critical role of metabolic pathways in aging. Diabetes (2012) 2.12
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol (2006) 2.05
Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes (2008) 2.00
Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev (2012) 1.99
Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal (2010) 1.99
Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest (2010) 1.97
SIRT1 and insulin resistance. Nat Rev Endocrinol (2009) 1.96
Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol Cell Biol (2010) 1.94
Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res Rev (2006) 1.94
Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst Biol (2009) 1.94
Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell (2006) 1.93
Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci (2011) 1.93
Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys (2010) 1.91
Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest (2010) 1.90
Tumor necrosis factor α-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. Arthritis Rheum (2011) 1.88
Vasoprotective effects of resveratrol and SIRT1: attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am J Physiol Heart Circ Physiol (2008) 1.87
Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev (2011) 1.85
Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-κB signalling. Nat Commun (2011) 1.84
Microglial activation in stroke: therapeutic targets. Neurotherapeutics (2010) 1.84
SIRT1 protects against emphysema via FOXO3-mediated reduction of premature senescence in mice. J Clin Invest (2012) 1.82
Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol (2007) 1.81
SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol (2009) 1.79
Calorie restriction and sirtuins revisited. Genes Dev (2013) 1.79
The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res (2009) 1.77
SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci (2010) 1.71
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol (2006) 1.68
Cellular stress response pathways and ageing: intricate molecular relationships. EMBO J (2011) 1.66
SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol Biol Cell (2008) 1.66
Regulation of cartilage-specific gene expression in human chondrocytes by SirT1 and nicotinamide phosphoribosyltransferase. J Biol Chem (2008) 1.66
DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1. J Biol Chem (2010) 1.65
Sirtuin 1 in lipid metabolism and obesity. Ann Med (2011) 1.65
Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: a role of lipid mobilization and inflammation. Endocrinology (2010) 1.65
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood (2014) 1.65
Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol (2009) 1.62
Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal (2010) 1.59
Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev (2010) 1.58
Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol (2008) 1.57
NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J (2006) 1.57
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther (2013) 1.57
Mammalian circadian clock and metabolism - the epigenetic link. J Cell Sci (2010) 1.55
NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J Biol Chem (2012) 1.55
Quantitative acetylome analysis reveals the roles of SIRT1 in regulating diverse substrates and cellular pathways. Mol Cell Proteomics (2012) 1.54
SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J (2010) 1.54
Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res (2015) 1.53
Sirt1, a negative regulator of matrix metalloproteinase-9 in diabetic retinopathy. Invest Ophthalmol Vis Sci (2014) 1.52
Nampt/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol (2006) 1.49
Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther (2009) 1.48
Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes (2010) 1.48
Retracted The effect of marathon on mRNA expression of anti-apoptotic and pro-apoptotic proteins and sirtuins family in male recreational long-distance runners. BMC Physiol (2010) 1.47
Sorting out functions of sirtuins in cancer. Oncogene (2013) 1.47
SIRT1 is a regulator in high glucose-induced inflammatory response in RAW264.7 cells. PLoS One (2015) 1.46
NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J Biol Chem (2011) 1.46
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature (2003) 17.52
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene (1999) 13.46
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science (1997) 10.90
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun (2000) 9.09
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. Nature (2002) 8.45
The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell (2003) 8.34
Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (2001) 6.79
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37
The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J (1991) 6.08
Sir2 links chromatin silencing, metabolism, and aging. Genes Dev (2000) 5.95
The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell (2002) 5.84
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol (2003) 5.46
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell (2003) 5.23
Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell (2002) 5.15
Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J (2002) 4.91
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 4.55
Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J (2003) 4.22
Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell (2004) 3.73
Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem (2002) 3.48
Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol (1999) 3.11
Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J (2003) 2.97
Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol (2000) 2.86
Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem Biophys Res Commun (2000) 2.65
Human Sir2-related protein SIRT1 associates with the bHLH repressors HES1 and HEY2 and is involved in HES1- and HEY2-mediated transcriptional repression. Biochem Biophys Res Commun (2003) 2.27
Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription. EMBO J (2001) 2.24
Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A (2001) 2.23
The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta (2000) 2.20
Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res (2000) 2.18
Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem (1998) 2.02
Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J Biol Chem (1998) 1.95
Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression. J Biol Chem (2003) 1.93
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem (2003) 1.73
Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res (2004) 1.67
RAC-3 is a NF-kappa B coactivator. FEBS Lett (2000) 1.64
A Drosophila homologue of Sir2 modifies position-effect variegation but does not affect life span. Genetics (2002) 1.63
Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha -, CD40-, and epstein-barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem (2000) 1.46
Diversity in the Sir2 family of protein deacetylases. J Leukoc Biol (2004) 1.33
Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBO J (1997) 1.31
Ras regulation of NF-kappa B and apoptosis. Methods Enzymol (2001) 1.30
Comparison of two methods to detect publication bias in meta-analysis. JAMA (2006) 7.34
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J (2002) 6.37
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol (2002) 5.37
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg (2011) 5.14
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem (2004) 3.39
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
To RCT or not to RCT: deciding when 'more evidence is needed' for public health policy and practice. J Epidemiol Community Health (2011) 3.26
How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med (2005) 2.95
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol (2008) 2.93
Video-assisted thoracic surgery versus open lobectomy for lung cancer: a secondary analysis of data from the American College of Surgeons Oncology Group Z0030 randomized clinical trial. J Thorac Cardiovasc Surg (2010) 2.31
SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell (2004) 2.27
Monitoring mortality rates in general practice after Shipman. BMJ (2003) 2.26
STS database risk models: predictors of mortality and major morbidity for lung cancer resection. Ann Thorac Surg (2010) 2.25
COMMD proteins, a novel family of structural and functional homologs of MURR1. J Biol Chem (2005) 2.24
A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B (2006) 2.23
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg (2012) 2.20
Predicted risk of mortality models: surgeons need to understand limitations of the University HealthSystem Consortium models. J Am Coll Surg (2009) 2.10
IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol (2006) 2.05
Ten-year experience on 644 patients undergoing single-port (uniportal) video-assisted thoracoscopic surgery. Ann Thorac Surg (2013) 2.01
Special treatment issues in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.94
Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol (2011) 1.93
Involvement of the histone deacetylase SIRT1 in chicken ovalbumin upstream promoter transcription factor (COUP-TF)-interacting protein 2-mediated transcriptional repression. J Biol Chem (2003) 1.93
Factors affecting uptake of childhood immunisation: a Bayesian synthesis of qualitative and quantitative evidence. Lancet (2002) 1.91
Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg (2002) 1.91
Finding qualitative research: an evaluation of search strategies. BMC Med Res Methodol (2004) 1.89
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med (2007) 1.83
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem (2003) 1.73
A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med (2003) 1.72
Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol Cell (2007) 1.70
Primary payer status affects mortality for major surgical operations. Ann Surg (2010) 1.69
Generation of phytate-free seeds in Arabidopsis through disruption of inositol polyphosphate kinases. Proc Natl Acad Sci U S A (2005) 1.68
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol (2006) 1.68
The impact of the lung allocation score on short-term transplantation outcomes: a multicenter study. J Thorac Cardiovasc Surg (2007) 1.65
GCN5 is a required cofactor for a ubiquitin ligase that targets NF-kappaB/RelA. Genes Dev (2009) 1.62
Comparative analysis of showering protocols for mass-casualty decontamination. Prehosp Disaster Med (2010) 1.62
Methodology and reporting of systematic reviews and meta-analyses of observational studies in psychiatric epidemiology: systematic review. Br J Psychiatry (2012) 1.60
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. J Thorac Cardiovasc Surg (2011) 1.59
High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer (2005) 1.55
Differences in reported esophageal cancer resection outcomes between national clinical and administrative databases. J Thorac Cardiovasc Surg (2012) 1.54
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
EUS-FNA as the initial diagnostic modality in centrally located primary lung cancers. J Clin Gastroenterol (2007) 1.51
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos (2010) 1.50
A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res (2004) 1.47
LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell (2007) 1.47
Intraoperative factors and the risk of respiratory complications after pneumonectomy. Ann Thorac Surg (2011) 1.45
Visualization of PtdIns3P dynamics in living plant cells. Plant J (2006) 1.44
A novel technique for localization and excisional biopsy of small or ill-defined pulmonary lesions. Ann Thorac Surg (2004) 1.43
Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med (2007) 1.40
Biallelic mutations in IRF8 impair human NK cell maturation and function. J Clin Invest (2016) 1.39
Evidence synthesis as the key to more coherent and efficient research. BMC Med Res Methodol (2009) 1.39
The use of systematic reviews when designing studies. Clin Trials (2005) 1.39
Evidence-based sample size calculations based upon updated meta-analysis. Stat Med (2007) 1.35
Metabolic costs of foraging and the management of O2 and CO2 stores in Steller sea lions. J Exp Biol (2008) 1.34
Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem (2006) 1.30
Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol (2015) 1.24
Existing general population models inaccurately predict lung cancer risk in patients referred for surgical evaluation. Ann Thorac Surg (2011) 1.23
Application of machine learning methods to histone methylation ChIP-Seq data reveals H4R3me2 globally represses gene expression. BMC Bioinformatics (2010) 1.22
Leiomyoma presenting as a massive calcified circumferential esophageal mass. Ann Thorac Surg (2013) 1.19
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest (2016) 1.18
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg (2012) 1.18
In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev (2013) 1.17
Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.17
T cell activation in vivo targets diacylglycerol kinase alpha to the membrane: a novel mechanism for Ras attenuation. J Immunol (2003) 1.15
PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem (2002) 1.15
T-B+NK+ severe combined immunodeficiency caused by complete deficiency of the CD3zeta subunit of the T-cell antigen receptor complex. Blood (2006) 1.15
Exercise warms adult leatherback turtles. Comp Biochem Physiol A Mol Integr Physiol (2006) 1.15
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg (2004) 1.13
Hospital procedure volume should not be used as a measure of surgical quality. Ann Surg (2012) 1.09
Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg (2010) 1.09
Does reperfusion injury still cause significant mortality after lung transplantation? J Thorac Cardiovasc Surg (2009) 1.09
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg (2004) 1.09
Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects. Stat Med (2005) 1.09
Comments on 'trying to be precise about vagueness' by Stephen Senn, Statistics in Medicine 2007; 26:1417-1430. Stat Med (2008) 1.07
NF-κB regulates mesenchymal transition for the induction of non-small cell lung cancer initiating cells. PLoS One (2013) 1.06
Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos (2002) 1.06
Radiotracer-guided thoracoscopic resection is a cost-effective technique for the evaluation of subcentimeter pulmonary nodules. Ann Thorac Surg (2008) 1.05
Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther (2007) 1.04
Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. J Clin Epidemiol (2010) 1.04
Deep diving mammals: Dive behavior and circulatory adjustments contribute to bends avoidance. Respir Physiol Neurobiol (2006) 1.03
Nuclear phosphoinositides and their impact on nuclear functions. FEBS J (2013) 1.02
Behaviour and physiology: the thermal strategy of leatherback turtles. PLoS One (2010) 1.02
PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. Biomaterials (2012) 1.02
Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol Cancer Ther (2011) 1.00
Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis. Bioorg Med Chem (2013) 1.00
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg (2004) 1.00
Obesity does not increase complications after anatomic resection for non-small cell lung cancer. Ann Thorac Surg (2007) 0.99
Direct regulation of striated muscle myosins by nitric oxide and endogenous nitrosothiols. PLoS One (2010) 0.99